Mechanisms of Bone Destruction in Myeloma

Rebecca Silbermann; G. David Roodman

doi:10.1016/B978-0-12-415853-5.00062-5

Mechanisms of Bone Destruction in Myeloma

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90% of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.

Original language	English (US)
Title of host publication	Osteoporosis
Subtitle of host publication	Fourth Edition
Publisher	Elsevier Inc.
Pages	1465-1478
Number of pages	14
ISBN (Print)	9780124158535
DOIs	https://doi.org/10.1016/B978-0-12-415853-5.00062-5
State	Published - Jun 2013
Externally published	Yes

Keywords

Bisphosphonate
Bone destruction
Multiple myeloma (MM)
Nuclear factor-kappaB/receptor activator
OBL suppression

ASJC Scopus subject areas

General Dentistry
General Medicine

Access to Document

10.1016/B978-0-12-415853-5.00062-5

Cite this

@inbook{b3ed5fb481ea4f8b80ea3819bb5ff7be,

title = "Mechanisms of Bone Destruction in Myeloma",

abstract = "Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90% of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.",

keywords = "Bisphosphonate, Bone destruction, Multiple myeloma (MM), Nuclear factor-kappaB/receptor activator, OBL suppression",

author = "Rebecca Silbermann and Roodman, {G. David}",

year = "2013",

month = jun,

doi = "10.1016/B978-0-12-415853-5.00062-5",

language = "English (US)",

isbn = "9780124158535",

pages = "1465--1478",

booktitle = "Osteoporosis",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Mechanisms of Bone Destruction in Myeloma

AU - Silbermann, Rebecca

AU - Roodman, G. David

PY - 2013/6

Y1 - 2013/6

N2 - Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90% of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.

AB - Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90% of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.

KW - Bisphosphonate

KW - Bone destruction

KW - Multiple myeloma (MM)

KW - Nuclear factor-kappaB/receptor activator

KW - OBL suppression

UR - http://www.scopus.com/inward/record.url?scp=84903082391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903082391&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-415853-5.00062-5

DO - 10.1016/B978-0-12-415853-5.00062-5

M3 - Chapter

AN - SCOPUS:84903082391

SN - 9780124158535

SP - 1465

EP - 1478

BT - Osteoporosis

PB - Elsevier Inc.

ER -

Mechanisms of Bone Destruction in Myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this